Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

R. Frank Cornell, MD MS, Adriana C Rossi, MD, MSc, Rachid Baz, MD, Craig C Hofmeister, Chaim Shustik, MD, Joshua R. Richter, MD, Christine Chen, MD, Dan T. Vogl, MD, Sharon Shacham, PhD MBA, Erkan Baloglu, PhD MBA, William Senapedis, PhD, Joel Ellis, PhD, Sharon Friedlander, PhD, Cassandra Choe-Juliak, MD, Christopher L Cubitt, PhD, Joel G Turner, PhD, Daniel Sullivan, MD MS, Michael Kauffman, MD PhD

Blood (2016) 128 (22): 4509.

https://doi.org/10.1182/blood.V128.22.4509.4509

Published: 2016

Journal Articles

A Phase 2 Study of High-Dose Melphalan Plus Bortezomib (Mel/Vel) Conditioning Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Taiga Nishihori, MD, Jose L Ochoa-Bayona, MD, Rachid Baz, MD, Kenneth H. Shain, MD PhD, Christine Simonelli, RN, Chiaka Nwoga, MPH, CCRP, Ryan Hillgruber, Daniel Sullivan, MD MS, Claudio Anasetti, MD, Melissa Alsina, MD

Blood (2014) 124 (21): 3987.

https://doi.org/10.1182/blood.V124.21.3987.3987

Published: 2014

Journal Articles

Cerebrospinal Fluid (CSF) Involvement By Plasma Cell Dyscrasias – Single Center Experience

Taiga Nishihori, MD, Jun Zhou, MD, Kenneth H. Shain, MD PhD, Rachid Baz, MD, Melissa Alsina, MD, Daniel Sullivan, MD MS, Ryan Hillgruber, Elizabeth M. Sagatys, MD, Lynn C. Moscinski, MD, Ling Zhang, MD

Blood (2014) 124 (21): 5686.

https://doi.org/10.1182/blood.V124.21.5686.5686

Published: 2014

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Using Fludarabine, Melphalan and Bortezomib (Flu/Mel/Vel) Conditioning For Consolidation Of VGPR Or CR In Myeloma

Taiga Nishihori, MD, Jose L. Ochoa-Bayona, MD, Kenneth H. Shain, MD, PhD, Daniel Sullivan, MD, Rachid Baz, MD, Ryan Hillgruber, Claudio Anasetti, MD, Melissa Alsina, MD

Blood (2013) 122 (21): 3390.

https://doi.org/10.1182/blood.V122.21.3390.3390

Published: 2013

Journal Articles

Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults with Newly Diagnosed Standard Risk Multiple Myeloma

Rachid Baz, MD, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Jennifer Paleveda, Nancy Hillgruber, RN, Elizabeth Finley-Oliver, RN, Leonel Ochoa, MD, Taiga Nishihori, MD, William Dalton, PhD, MD, Daniel Sullivan, MD

Blood (2012) 120 (21): 4060.

https://doi.org/10.1182/blood.V120.21.4060.4060

Published: 2012

Journal Articles

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Lubomir Sokol, MD, PhD, Kristy L. Richards, PhD, MD, Samir Parekh, MD, Rebecca Elstrom, MD, Ashraf Z. Badros, MD, Igor Espinoza-Delgado, MD, Michael J. Schell, PhD, Amy Kimball, MD, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Domenico Coppola, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, John D. Roberts, MD, Steven Grant, MD

Blood (2011) 118 (21): 779.

https://doi.org/10.1182/blood.V118.21.779.779

Published: 2011

Journal Articles

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth H. Shain, MD, PhD, Daniel Sullivan, MD, Melissa Alsina, MD, Leonel Ochoa, Taiga Nishihori, MD, Benjamin Djulbegovic, MD, PhD, William Dalton, PhD, MD, Rachid Baz, MD

Blood (2011) 118 (21): 3979.

https://doi.org/10.1182/blood.V118.21.3979.3979

Published: 2011

Journal Articles

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

Adriana Zingone, MD, PhD, Neha Korde, MD, Jinqiu Chen, PhD, Liqiang Xi, MD, Mark Raffeld, MD, Beata Holkova, MD, Maciej Kmieciak, PhD, Daniel Sullivan, MD, Austin Doyle, MD, Irina Maric, MD, Katherine Calvo, MD, PhD, Mary Ann Yancey, RN, Marcia Mulquin, RN, Christina Annunziata, MD, PhD, Steven Grant, MD, Ola Landgren, MD, PhD

Blood (2011) 118 (21): 306.

https://doi.org/10.1182/blood.V118.21.306.306

Published: 2011

Journal Articles

A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma

Beata Holkova, MD, Ashraf Z. Badros, MD, Robert Geller, MD, Peter M. Voorhees, MD, Adriana Zingone, MD, PhD, Neha Korde, MD, Hui-Yi Lin, PhD, Mary Beth Tombes, RN, Ellen Shrader, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Daniel Sullivan, MD, Ola Landgren, MD, PhD, Steven Grant, MD

Blood (2011) 118 (21): 2931.

https://doi.org/10.1182/blood.V118.21.2931.2931

Published: 2011

Journal Articles

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Rachid Baz, MD, Amila M Patel, PharmD, Viet Q. Ho, PharmD, BCOP, Kenneth Shain, MD, PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Jose Leonel Ochoa-Bayona, M.D., Daniel Sullivan, MD, Benjamin Djulbegovic, MD, PhD, William S. Dalton, PhD, MD

Blood (2011) 118 (21): 1878.

https://doi.org/10.1182/blood.V118.21.1878.1878

Published: 2011

Journal Articles

Novel Drug Targets to Overcome De Novo Drug-Resistance In Multiple Myeloma

Joel G Turner, PhD, Thomas C Rowe, PhD, David Ostrov, Jana L Dawson, BS, Elizabeth Ciaravino, BS, Daniel Sullivan, MD

Blood (2010) 116 (21): 3006.

https://doi.org/10.1182/blood.V116.21.3006.3006

Published: 2010

Journal Articles

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Janelle Perkins, PharmD, Teresa Field, MD, PhD, Jongphil Kim, PhD, Hugo F. Fernandez, MD, Lia Perez, MD, Ernesto Ayala, MD, Mohamed Kharfan-Dabaja, MD, Marcie Tomblyn, MD, MS, Daniel Sullivan, MD, Claudio Anasetti, MD

Blood (2010) 116 (21): 3499.

https://doi.org/10.1182/blood.V116.21.3499.3499

Published: 2010

Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib

Paul G Richardson, MD, David Siegel, MD, PhD, Rachid Baz, MD, Susan L. Kelley, MD, Nikhil C. Munshi, MD, Daniel Sullivan, MD, Melissa Alsina, MD, Deborah Doss, RN, OCN, Laura McBride, Gail Larkins, RN, Maria Lizza, BS, Xin Yu, Mohamed Zaki, MD, Christian J. Jacques, MD, Kenneth C. Anderson, MD

Blood (2010) 116 (21): 864.

https://doi.org/10.1182/blood.V116.21.864.864

Published: 2010

Journal Articles

Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience

Elizabeth Finley-Oliver, RN, Kenneth Shain, MD, PhD, Taiga Nishihori, MD, Jose-Leonel Ochoa-Bayona, M.D., Melissa Alsina, MD, Daniel Sullivan, MD, William S. Dalton, PhD, MD, Rachid Baz, MD

Blood (2010) 116 (21): 4756.

https://doi.org/10.1182/blood.V116.21.4756.4756

Published: 2010

Journal Articles

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Rachid Baz, MD, Mohamad A Hussein, MD, Daniel Sullivan, MD, Jose-Leonel Ochoa-Bayona, M.D., Monique A Hartley, MD, Kenneth Shain, MD, PhD, Taiga Nishihori, MD, Jennifer Paleveda, Kara Kosakowski, William S. Dalton, PhD, MD, Melissa Alsina, MD

Blood (2010) 116 (21): 3054.

https://doi.org/10.1182/blood.V116.21.3054.3054

Published: 2010

Journal Articles

Preclinical Development of Small-Molecule CRM1 Inhibitors as Novel Therapy for the Treatment of Myeloma and Other Hematological Malignancies

Sharon Shacham, PhD, MBA, Joel G Turner, PhD, Raphael Nir, Giulio Draetta, Vincent Sandanayaka, Sharon Shechter, Michael Kauffman, Daniel Sullivan, MD

Blood (2010) 116 (21): 3012.

https://doi.org/10.1182/blood.V116.21.3012.3012

Published: 2010

Journal Articles

Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience

Blood (2008) 112 (11): 4435.

https://doi.org/10.1182/blood.V112.11.4435.4435

Published: 2008

Journal Articles

A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.

Jeffrey E. Lancet, MD, Elliott F. Winton, MD, Robert K. Stuart, MD, Michelle Burton, RN, Christopher Cubitt, PhD, Michelle Blaskovich, John Wright, MD, PhD, Said Sebti, PhD, Daniel Sullivan, MD, MS

Blood (2008) 112 (11): 1945.

https://doi.org/10.1182/blood.V112.11.1945.1945

Published: 2008

Journal Articles

Intrinsic Drug Resistance in Multiple Myeloma to Doxorubicin Is Mediated by Soluble Factors

Daniel Sullivan, MD, MS, Jana L. Dawson, Elizabeth J. Ciaravino, Joel G. Turner, Ph.D.

Blood (2008) 112 (11): 5106.

https://doi.org/10.1182/blood.V112.11.5106.5106

Published: 2008

Journal Articles

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Daniel Sullivan, MD, Melissa Alsina, MD, Claudio Anasetti, MD, Teresa Field, MD, PhD, Mohamed Kharfan-Dabaja, MD, Hugo Fernandez, MD, William Dalton, PhD, MD, Ernesto Ayala, MD, Jyoti Raychaudhuri, MD, Lia Perez, MD, Janelle Perkins, PharmD, Michael Schell, PhD, Christine McIsaac, RN, Beth Maddox, RN, Jana Gump, BS, Richard Lush, PhD, Tony Frudakis, PhD

Blood (2007) 110 (11): 943.

https://doi.org/10.1182/blood.V110.11.943.943

Published: 2007

NARROW

A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma

A Phase 2 Study of High-Dose Melphalan Plus Bortezomib (Mel/Vel) Conditioning Followed By Autologous Hematopoietic Cell Transplantation in Myeloma

Cerebrospinal Fluid (CSF) Involvement By Plasma Cell Dyscrasias – Single Center Experience

Allogeneic Hematopoietic Cell Transplantation Using Fludarabine, Melphalan and Bortezomib (Flu/Mel/Vel) Conditioning For Consolidation Of VGPR Or CR In Myeloma

Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults with Newly Diagnosed Standard Risk Multiple Myeloma

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Sequence of Therapy in Multiple Myeloma: Does It Matter? Retrospective Evaluation of Patients with Multiple Myeloma Who Have Received Bortezomib Followed by Lenalidomide or Vice Versa,

Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study

A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma

Outcomes Analysis of Doublets of Novel Agents with Corticosteroids Versus Regimens with 3 or More Agents for Multiple Myeloma (MM): A Retrospective Analysis

Novel Drug Targets to Overcome De Novo Drug-Resistance In Multiple Myeloma

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Treatments and Outcomes of Patients with Multiple Myeloma (MM) Older Than 75 Years of Age: A Single Institution Experience

Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)

Preclinical Development of Small-Molecule CRM1 Inhibitors as Novel Therapy for the Treatment of Myeloma and Other Hematological Malignancies

Age Is the Strongest Independent Prognostic Factor in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: Moffitt Cancer Center Experience

A Phase 1 Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias.

Intrinsic Drug Resistance in Multiple Myeloma to Doxorubicin Is Mediated by Soluble Factors

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only